Curator22
@reelda
India is seeing a growing interest in GLP-1 treatments as diabetes and obesity rates climb. Eli Lilly released Mounjaro (tirzepatide) in March 2025 for managing these conditions. Meanwhile, Novo Nordisk has its own plans in the pipeline.
0 reply
0 recast
0 reaction